Fasting Insulin and HOMA-IR: The Earliest Sign of Insulin Resistance

Insulin is the master anabolic hormone, released from pancreatic beta cells in response to glucose, amino acids, and certain gut peptides. Its job is to push glucose into muscle and fat, suppress hepatic glucose output, and switch the body from "burn" to "store." Fasting insulin captures the basal level after 8+ hours without food, when nothing should be stimulating release.

In a metabolically healthy person, fasting insulin is low because the pancreas does not need to push hard. When sensitivity falls (visceral fat, sedentary life, genetic predisposition), the pancreas makes more insulin to achieve the same glucose control. That is what an elevated fasting insulin means: the cells are not listening to the original dose, so the body shouts.

The progression to type 2 diabetes is slow. Glucose stays normal for years because the compensation works. Then post-meal glucose creeps up (impaired glucose tolerance). Then fasting glucose drifts (impaired fasting glucose). Finally HbA1c rises into the prediabetes and diabetes range. By that point the disease has been quietly progressing for a decade.

Standard immunoassay reports fasting insulin in µIU/mL (or pmol/L; multiply µIU/mL by ~6 to convert). Some labs include C-peptide, a related but more stable marker preferred in some research contexts.

Lab reference ranges for fasting insulin are wide and forgiving, often something like 2.6 to 24.9 µIU/mL. That upper limit reflects what the population looks like, not what is healthy. In metabolically optimal adults, fasting insulin runs much lower than the lab "normal":

• Optimal: below 7 µIU/mL (often below 5 in lean, active adults).
• Acceptable: 7 to 10 µIU/mL.
• Suggestive of insulin resistance: 10 to 15 µIU/mL.
• Significant insulin resistance: above 15 µIU/mL.
• Lab "normal" upper limit: typically 24 to 25 µIU/mL. Values that high are rarely actually normal.

HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) combines fasting insulin and fasting glucose into one number:

HOMA-IR = (fasting insulin in µIU/mL × fasting glucose in mg/dL) / 405

• Below 1.0: insulin sensitive.
• 1.0–2.5: probably normal.
• Above 2.5: insulin resistance likely.
• Above 5.0: significant insulin resistance.

Note: HOMA-IR cutoffs vary by population and assay; treat them as ranges, not bright lines. Source: Matthews et al. (1985), with subsequent population validation studies.

The early-warning interpretation

Elevated fasting insulin with normal fasting glucose is the classical pattern of compensated insulin resistance. The pancreas is working harder to keep glucose normal, and it is succeeding for now. This is also the window where lifestyle and dietary changes pay off most, because the machinery is still flexible.

Common drivers

• Visceral adiposity. The most common cause. Visceral fat can be substantial in people whose BMI looks fine ("thin outside, fat inside," TOFI), which is one reason fasting insulin catches problems BMI misses.
• Sedentary life. Skeletal muscle is the largest insulin-responsive tissue. Lack of contraction directly reduces glucose uptake.
• High refined-carbohydrate intake. Repeated large insulin spikes drive long-term resistance.
• Polycystic ovary syndrome (PCOS). Insulin resistance is part of the underlying mechanism. Fasting insulin and HOMA-IR are commonly used in PCOS evaluation.
• Family history of type 2 diabetes. Heritability of insulin resistance is substantial.
• Sleep deprivation and untreated sleep apnea.
• Chronic stress and cortisol elevation.
• Medications. Long-term corticosteroids, atypical antipsychotics (especially olanzapine, clozapine), some antiretrovirals, beta-blockers, thiazides.

What moves the number

Few labs respond as fast to lifestyle change as fasting insulin:

• Carbohydrate restriction. Low-carb and ketogenic interventions can drop fasting insulin by 50% or more within weeks, often before any meaningful weight loss.
• Weight loss, especially visceral fat. Each 5 to 10 kg of meaningful weight loss typically halves fasting insulin in resistant patients.
• Resistance training and high-intensity interval exercise. Increase glucose uptake into skeletal muscle independently of weight change.
• Time-restricted eating. Modest but reproducible reductions over months.
• Metformin. Lowers fasting insulin by 10 to 25% by reducing hepatic glucose output and improving sensitivity.
• SGLT2 inhibitors and GLP-1 receptor agonists. Reduce fasting insulin meaningfully through different mechanisms.

Most low fasting insulin readings are simply good news. A sign of a metabolically healthy pancreas in a metabolically healthy body. A fasting insulin of 4 µIU/mL with normal fasting glucose is not a problem.

Real concern attaches to low insulin only when paired with high glucose. That combination points to insulin deficiency, not sensitivity:

• Type 1 diabetes. Autoimmune destruction of beta cells. Insulin low or unmeasurable while glucose is high. C-peptide is the more useful confirmatory test.
• Late-stage type 2 with beta-cell exhaustion. After years of compensatory hyperinsulinemia, the pancreas can lose capacity. Previously high fasting insulin falls into the normal or low range while glucose rises. One signal that insulin therapy may eventually be needed.
• Latent autoimmune diabetes in adults (LADA). Slow autoimmune beta-cell destruction in adults, with progressive insulin deficiency.
• Pancreatic disease. Chronic pancreatitis, pancreatic resection.

Low fasting insulin with normal glucose, normal weight, and good metabolic health is not a problem to chase.

Fasting insulin swings 20 to 30% morning to morning without any underlying change. A single value of 12 in someone who usually runs 7 might just be a heavier dinner, poor sleep, or a high-carb week. Decisions should rest on a pattern, not a single result.

Patterns worth recognizing:

• Rising fasting insulin with stable glucose. Early insulin resistance, the highest-leverage intervention window. This is the pattern the test exists to catch.
• Falling fasting insulin with stable or improving glucose. Successful intervention. Carbohydrate restriction and weight loss show this within weeks.
• Falling fasting insulin with rising glucose. The worrying late pattern in long-standing type 2 diabetes. Beta-cell capacity is declining, and exogenous insulin may eventually be needed.
• High insulin paired with high glucose. Established insulin resistance with early decompensation. Time to act in a structured way.

For clinical decisions, two readings 2 to 4 weeks apart are more reliable than one. For tracking an intervention, recheck at 8 to 12 weeks: long enough for real change, short enough to keep momentum.

• Fasting insulin above 15 µIU/mL on two separate readings, normal glucose. Significant compensated insulin resistance. Lifestyle intervention is the right starting point: weight loss focused on visceral fat, resistance training, carbohydrate quality and quantity, sleep, stress.
• HOMA-IR above 2.5. Same picture. The combined number is sometimes more useful than insulin alone.
• Elevated fasting insulin with normal glucose, plus PCOS, fatty liver, or family history of type 2 diabetes. Strong indication for early intervention. Metformin is often considered alongside lifestyle change.
• Low fasting insulin with high glucose. Concerning for type 1 diabetes, LADA, or beta-cell exhaustion. Check C-peptide, GAD antibodies, consider endocrinology referral.
• Fasting insulin not changing despite serious lifestyle change. Rule out genetic insulin resistance syndromes, severe sleep apnea, and undertreated comorbidities. A second opinion from endocrinology is reasonable.

• Fasting glucose. Combined with fasting insulin to calculate HOMA-IR, the most useful summary of basal insulin resistance.
• HbA1c. Two- to three-month glucose average. In compensated insulin resistance, A1c is normal even when fasting insulin is high. Once A1c rises, the metabolic picture is already advanced.
• Triglycerides and HDL cholesterol. High triglycerides and low HDL are the most reliable lipid signature of insulin resistance. A triglyceride/HDL ratio above 3 is a useful surrogate when fasting insulin is unavailable.
• ALT. Non-alcoholic fatty liver disease tracks with insulin resistance. An unexplained mildly elevated ALT in a normal-weight person should prompt fasting insulin and HOMA-IR.
• Uric acid. Clusters with insulin resistance and metabolic syndrome.
• C-peptide. More stable measure of pancreatic insulin output. Preferred when distinguishing type 1 from type 2 diabetes or assessing beta-cell function.
• Oral glucose tolerance test with insulin levels. The more elaborate test. Measures insulin response to a glucose challenge. Useful in PCOS and in research settings.